{
  "DOI": "10.1186/s40246-023-00495-3",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-023-00495-3",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eBackground\u003c/jats:title\u003e\n                \u003cjats:p\u003eCardiovascular diseases and especially Acute Coronary Syndrome (ACS) constitute a major health issue impacting millions of patients worldwide. Being a leading cause of death and hospital admissions in many European countries including Spain, it accounts for enormous amounts of healthcare expenditures for its management. Clopidogrel is one of the oldest antiplatelet medications used as standard of care in ACS.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eMethods\u003c/jats:title\u003e\n                \u003cjats:p\u003eIn this study, we performed an economic evaluation study to estimate whether a genome-guided clopidogrel treatment is cost-effective compared to conventional one in a large cohort of 243 individuals of Spanish origin suffering from ACS and treated with clopidogrel. Data were derived from the U-PGx PREPARE clinical trial. Effectiveness was measured as survival of individuals while study data on safety and efficacy, as well as on resource utilization associated with each adverse drug reaction were used to measure costs to treat these adverse drug reactions. A generalized linear regression model was used to estimate cost differences for both study groups.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eResults\u003c/jats:title\u003e\n                \u003cjats:p\u003eBased on our findings, PGx-guided treatment group is cost-effective. PGx-guided treatment demonstrated to have 50% less hospital admissions, reduced emergency visits and almost 13% less ADRs compared to the non-PGx approach with mean QALY 1.07 (95% CI, 1.04–1.10) versus 1.06 (95% CI, 1.03–1.09) for the control group, while life years for both groups were 1.24 (95% CI, 1.20–1.26) and 1.23 (95% CI, 1.19–1.26), respectively. The mean total cost of PGx-guided treatment was 50% less expensive than conventional therapy with clopidogrel [€883 (95% UI, €316–€1582), compared to €1,755 (95% UI, €765–€2949)].\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eConclusion\u003c/jats:title\u003e\n                \u003cjats:p\u003eThese findings suggest that PGx-guided clopidogrel treatment represents a cost-effective option for patients suffering from ACS in the Spanish healthcare setting.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e",
  "alternative-id": [
    "495"
  ],
  "article-number": "51",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "16 April 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "24 May 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "7 June 2023"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethics approval and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "This study was approved by Comité Coordinador de Ética de la Investigación Biomédica de Andalucía (CCEIBA), ethics committee in Spain."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "All participants were given their written informed consent to publish their data before entering PREPARE trial."
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "The authors declare that they have no competing interests\" in this section."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Koufaki",
      "given": "Margarita-Ioanna",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Fragoulakis",
      "given": "Vasileios",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Díaz-Villamarín",
      "given": "Xando",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Karamperis",
      "given": "Kariofyllis",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Vozikis",
      "given": "Athanassios",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Swen",
      "given": "Jesse J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Dávila-Fajardo",
      "given": "Cristina L.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Vasileiou",
      "given": "Konstantinos Z.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Patrinos",
      "given": "George P.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Mitropoulou",
      "given": "Christina",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2023,
        6,
        7
      ]
    ],
    "date-time": "2023-06-07T15:03:17Z",
    "timestamp": 1686150197000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        6,
        8
      ]
    ],
    "date-time": "2023-06-08T03:27:22Z",
    "timestamp": 1686194842000
  },
  "funder": [
    {
      "DOI": "10.13039/100011103",
      "award": [
        "668353"
      ],
      "doi-asserted-by": "publisher",
      "name": "Sixth Framework Programme"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        29
      ]
    ],
    "date-time": "2024-04-29T07:52:10Z",
    "timestamp": 1714377130430
  },
  "is-referenced-by-count": 7,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2023,
        6,
        7
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2023,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            6,
            7
          ]
        ],
        "date-time": "2023-06-07T00:00:00Z",
        "timestamp": 1686096000000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            6,
            7
          ]
        ],
        "date-time": "2023-06-07T00:00:00Z",
        "timestamp": 1686096000000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00495-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-023-00495-3/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00495-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2023,
        6,
        7
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2023,
        6,
        7
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1161/CIRCULATIONAHA.119.038714",
      "author": "H Bueno",
      "doi-asserted-by": "publisher",
      "first-page": "13",
      "issue": "1",
      "journal-title": "Circulation",
      "key": "495_CR1",
      "unstructured": "Bueno H, Pérez-Gómez B. global rounds: cardiovascular health, disease, and care in Spain. Circulation. 2019;140(1):13–5.",
      "volume": "140",
      "year": "2019"
    },
    {
      "key": "495_CR2",
      "unstructured": "Cardiovascular Health Strategy Spain’s National Health System Executive Summary, March 2022."
    },
    {
      "key": "495_CR3",
      "unstructured": "Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, Burns R, Rayner M, Townsend N. European Cardiovascular Disease Statistics. European Heart Network, 2017; Brussels."
    },
    {
      "DOI": "10.1007/s11883-014-0401-9",
      "author": "CG Santos-Gallego",
      "doi-asserted-by": "publisher",
      "journal-title": "Curr Atheroscler Rep",
      "key": "495_CR4",
      "unstructured": "Santos-Gallego CG, Picatoste B, Badimón JJ. Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep. 2014. https://doi.org/10.1007/s11883-014-0401-9.",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.pop.2017.11.001",
      "author": "RP Lennon",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Prim Care",
      "key": "495_CR5",
      "unstructured": "Lennon RP, Claussen KA, Kuersteiner KA. State of the heart: an overview of the disease burden of cardiovascular disease from an epidemiologic perspective. Prim Care. 2018;45(1):1–15. https://doi.org/10.1016/j.pop.2017.11.001.",
      "volume": "45",
      "year": "2018"
    },
    {
      "DOI": "10.1136/openhrt-2016-000419",
      "author": "B Gencer",
      "doi-asserted-by": "publisher",
      "first-page": "e000419",
      "issue": "1",
      "journal-title": "Open Heart.",
      "key": "495_CR6",
      "unstructured": "Gencer B, Rodondi N, Auer R, Nanchen D, Räber L, Klingenberg R, et al. Health utility indexes in patients with acute coronary syndromes. Open Heart. 2016;3(1):e000419. https://doi.org/10.1136/openhrt-2016-000419.",
      "volume": "3",
      "year": "2016"
    },
    {
      "DOI": "10.1093/ehjcvp/pvab018.Erratum.In:EurHeartJCardiovascPharmacother.2022Dec15;9(1):116",
      "author": "EF Magavern",
      "doi-asserted-by": "publisher",
      "first-page": "85",
      "issue": "1",
      "journal-title": "Eur Heart J Cardiovasc Pharmacother",
      "key": "495_CR7",
      "unstructured": "Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother. 2022;8(1):85–99. https://doi.org/10.1093/ehjcvp/pvab018.Erratum.In:EurHeartJCardiovascPharmacother.2022Dec15;9(1):116.",
      "volume": "8",
      "year": "2022"
    },
    {
      "DOI": "10.1056/NEJMoa1907096",
      "author": "DMF Claassens",
      "doi-asserted-by": "publisher",
      "first-page": "1621",
      "issue": "17",
      "journal-title": "N Engl J Med",
      "key": "495_CR8",
      "unstructured": "Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van’t Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM, Ten Berg JM. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–31. https://doi.org/10.1056/NEJMoa1907096. (Epub 2019 Sep 3).",
      "volume": "381",
      "year": "2019"
    },
    {
      "DOI": "10.3390/jpm8010008",
      "author": "SA Brown",
      "doi-asserted-by": "publisher",
      "first-page": "8",
      "issue": "1",
      "journal-title": "J Pers Med",
      "key": "495_CR9",
      "unstructured": "Brown SA, Pereira N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine. J Pers Med. 2018;8(1):8. https://doi.org/10.3390/jpm8010008.",
      "volume": "8",
      "year": "2018"
    },
    {
      "DOI": "10.1002/cpt.2526",
      "author": "CR Lee",
      "doi-asserted-by": "publisher",
      "first-page": "959",
      "issue": "5",
      "journal-title": "Clin Pharmacol Ther",
      "key": "495_CR10",
      "unstructured": "Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112(5):959–67. https://doi.org/10.1002/cpt.2526.",
      "volume": "112",
      "year": "2022"
    },
    {
      "DOI": "10.1007/s40262-013-0105-2",
      "author": "M Karaźniewicz-Łada",
      "doi-asserted-by": "publisher",
      "first-page": "155",
      "issue": "2",
      "journal-title": "Clin Pharmacokinet",
      "key": "495_CR11",
      "unstructured": "Karaźniewicz-Łada M, Danielak D, Burchardt P, Kruszyna L, Komosa A, Lesiak M, Główka F. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet. 2014;53(2):155–64. https://doi.org/10.1007/s40262-013-0105-2.",
      "volume": "53",
      "year": "2014"
    },
    {
      "DOI": "10.1038/clpt.2013.105",
      "doi-asserted-by": "publisher",
      "key": "495_CR12",
      "unstructured": "Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–23. https://doi.org/10.1038/clpt.2013.105."
    },
    {
      "DOI": "10.1007/s40262-014-0230-6",
      "author": "XL Jiang",
      "doi-asserted-by": "publisher",
      "first-page": "147",
      "issue": "2",
      "journal-title": "Clin Pharmacokinet",
      "key": "495_CR13",
      "unstructured": "Jiang XL, Samant S, Lesko LJ, Schmidt S. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015;54(2):147–66. https://doi.org/10.1007/s40262-014-0230-6.",
      "volume": "54",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41431-019-0480-8",
      "author": "J Petrović",
      "doi-asserted-by": "publisher",
      "first-page": "88",
      "issue": "1",
      "journal-title": "Eur J Hum Genet",
      "key": "495_CR14",
      "unstructured": "Petrović J, Pešić V, Lauschke VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet. 2020;28(1):88–94. https://doi.org/10.1038/s41431-019-0480-8.",
      "volume": "28",
      "year": "2020"
    },
    {
      "DOI": "10.1093/ehjcvp/pvz045",
      "doi-asserted-by": "publisher",
      "key": "495_CR15",
      "unstructured": "Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR; ICPC Investigators. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):203–210. https://doi.org/10.1093/ehjcvp/pvz045."
    },
    {
      "DOI": "10.1001/jama.2020.12443",
      "author": "NL Pereira",
      "doi-asserted-by": "publisher",
      "first-page": "761",
      "issue": "8",
      "journal-title": "JAMA",
      "key": "495_CR16",
      "unstructured": "Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324(8):761–71. https://doi.org/10.1001/jama.2020.12443.",
      "volume": "324",
      "year": "2020"
    },
    {
      "key": "495_CR17",
      "unstructured": "Center for Drug Evaluation and Research. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. U.S. Food and Drug Administration.2017; https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor"
    },
    {
      "DOI": "10.1038/clpt.2011.34",
      "author": "JJ Swen",
      "doi-asserted-by": "publisher",
      "first-page": "662",
      "issue": "5",
      "journal-title": "Clin Pharmacol Ther",
      "key": "495_CR18",
      "unstructured": "Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73. https://doi.org/10.1038/clpt.2011.34.",
      "volume": "89",
      "year": "2011"
    },
    {
      "DOI": "10.1093/eurheartj/ehab892",
      "doi-asserted-by": "publisher",
      "key": "495_CR19",
      "unstructured": "Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, Kazakiewicz D, de Benito Rubio V, Ignatiuk B, Raisi-Estabragh Z, Pawlak A, Karagiannidis E, Treskes R, Gaita D, Beltrame JF, McConnachie A, Bardinet I, Graham I, Flather M, Elliott P, Mossialos EA, Weidinger F, Achenbach S; Atlas Writing Group, European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022 22;43(8):716–799. https://doi.org/10.1093/eurheartj/ehab892."
    },
    {
      "DOI": "10.1016/j.xphs.2017.04.051",
      "author": "ME Klein",
      "doi-asserted-by": "publisher",
      "first-page": "2368",
      "issue": "9",
      "journal-title": "J Pharm Sci",
      "key": "495_CR20",
      "unstructured": "Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J Pharm Sci. 2017;106(9):2368–79. https://doi.org/10.1016/j.xphs.2017.04.051.",
      "volume": "106",
      "year": "2017"
    },
    {
      "DOI": "10.1161/CIRCINTERVENTIONS.119.007811",
      "author": "NL Pereira",
      "doi-asserted-by": "publisher",
      "first-page": "e007811",
      "issue": "4",
      "journal-title": "Circ Cardiovasc Interv",
      "key": "495_CR21",
      "unstructured": "Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME. Clopidogrel Pharmacogenetics. Circ Cardiovasc Interv. 2019;12(4):e007811. https://doi.org/10.1161/CIRCINTERVENTIONS.119.007811.",
      "volume": "12",
      "year": "2019"
    },
    {
      "DOI": "10.2217/pgs-2017-0093",
      "author": "LE Manson",
      "doi-asserted-by": "publisher",
      "first-page": "1041",
      "issue": "11",
      "journal-title": "Pharmacogenomics",
      "key": "495_CR22",
      "unstructured": "Manson LE, van der Wouden CH, Swen JJ, Guchelaar HJ. The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen. Pharmacogenomics. 2017;18(11):1041–5. https://doi.org/10.2217/pgs-2017-0093.",
      "volume": "18",
      "year": "2017"
    },
    {
      "DOI": "10.1002/cpt.602",
      "doi-asserted-by": "publisher",
      "key": "495_CR23",
      "unstructured": "van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther. 2017;101(3):341–358. https://doi.org/10.1002/cpt.602."
    },
    {
      "DOI": "10.1016/s0140-6736(22)01841-4",
      "author": "JJ Swen",
      "doi-asserted-by": "publisher",
      "first-page": "347",
      "issue": "10374",
      "journal-title": "Lancet",
      "key": "495_CR24",
      "unstructured": "Swen JJ, Van Der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347–56. https://doi.org/10.1016/s0140-6736(22)01841-4.",
      "volume": "401",
      "year": "2023"
    },
    {
      "key": "495_CR25",
      "unstructured": "Comité Coordinador de Ética de la Investigación Biomédica de Andalucía (CCEIBA) https://www.bioetica-andalucia.es/3-comites-de-etica/3-2-comite-coordinador-de-etica-de-la-investigacion-biomedica-de-andalucia-cceiba/"
    },
    {
      "key": "495_CR26",
      "unstructured": "Available at: https://yhec.co.uk/glossary/perspective/ ), accessed at [10-06-2022]"
    },
    {
      "DOI": "10.1080/14737167.2016.1259571",
      "author": "AL Gordois",
      "doi-asserted-by": "publisher",
      "first-page": "759",
      "issue": "6",
      "journal-title": "Expert Rev Pharmacoeconomics Outcomes Res",
      "key": "495_CR27",
      "unstructured": "Gordois AL, Toth PP, Quek RG, Proudfoot EM, Paoli CJ, Gandra SR. Productivity losses associated with cardiovascular disease: a systematic review. Expert Rev Pharmacoeconomics Outcomes Res. 2016;16(6):759–69. https://doi.org/10.1080/14737167.2016.1259571.",
      "volume": "16",
      "year": "2016"
    },
    {
      "DOI": "10.1007/s10198-020-01166-z",
      "author": "B Michalowsky",
      "doi-asserted-by": "publisher",
      "first-page": "717",
      "journal-title": "Eur J Health Econ",
      "key": "495_CR28",
      "unstructured": "Michalowsky B, Hoffmann W, Kennedy K, et al. Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials. Eur J Health Econ. 2020;21:717–28.",
      "volume": "21",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s40273-014-0193-3",
      "author": "R Faria",
      "doi-asserted-by": "publisher",
      "first-page": "1157",
      "issue": "12",
      "journal-title": "Pharmacoeconomics",
      "key": "495_CR29",
      "unstructured": "Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics. 2014;32(12):1157–70. https://doi.org/10.1007/s40273-014-0193-3.",
      "volume": "32",
      "year": "2014"
    },
    {
      "DOI": "10.1007/s41669-017-0015-6.Erratum.In:PharmacoeconOpen.2017Jun;1(2):143",
      "author": "A Gabrio",
      "doi-asserted-by": "publisher",
      "first-page": "79",
      "issue": "2",
      "journal-title": "Pharmacoecon Open",
      "key": "495_CR30",
      "unstructured": "Gabrio A, Mason AJ, Baio G. Handling missing data in within-trial cost-effectiveness analysis: a review with future recommendations. Pharmacoecon Open. 2017;1(2):79–97. https://doi.org/10.1007/s41669-017-0015-6.Erratum.In:PharmacoeconOpen.2017Jun;1(2):143.",
      "volume": "1",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.jval.2022.02.009",
      "author": "X Ling",
      "doi-asserted-by": "publisher",
      "first-page": "1654",
      "issue": "9",
      "journal-title": "Value Health",
      "key": "495_CR31",
      "unstructured": "Ling X, Gabrio A, Mason A, Baio G. A scoping review of item-level missing data in within-trial cost-effectiveness analysis. Value Health. 2022;25(9):1654–62. https://doi.org/10.1016/j.jval.2022.02.009.",
      "volume": "25",
      "year": "2022"
    },
    {
      "DOI": "10.1186/s12913-021-06513-1",
      "author": "EN Mutubuki",
      "doi-asserted-by": "publisher",
      "first-page": "475",
      "issue": "1",
      "journal-title": "BMC Health Serv Res",
      "key": "495_CR32",
      "unstructured": "Mutubuki EN, El Alili M, Bosmans JE, Oosterhuis T, J Snoek F, Ostelo RWJG, van Tulder MW, van Dongen JM. The statistical approach in trial-based economic evaluations matters: get your statistics together! BMC Health Serv Res. 2021;21(1):475. https://doi.org/10.1186/s12913-021-06513-1.",
      "volume": "21",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.bjpt.2021.06.011",
      "author": "GC Miyamoto",
      "doi-asserted-by": "publisher",
      "first-page": "514",
      "issue": "5",
      "journal-title": "Braz J Phys Ther",
      "key": "495_CR33",
      "unstructured": "Miyamoto GC, Ben ÂJ, Bosmans JE, van Tulder MW, Lin CC, Cabral CMN, van Dongen JM. Interpretation of trial-based economic evaluations of musculoskeletal physical therapy interventions. Braz J Phys Ther. 2021;25(5):514–29. https://doi.org/10.1016/j.bjpt.2021.06.011.",
      "volume": "25",
      "year": "2021"
    },
    {
      "DOI": "10.1186/s12874-017-0442-1",
      "author": "JC Jakobsen",
      "doi-asserted-by": "publisher",
      "first-page": "162",
      "issue": "1",
      "journal-title": "BMC Med Res Methodol",
      "key": "495_CR34",
      "unstructured": "Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials—a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162. https://doi.org/10.1186/s12874-017-0442-1.",
      "volume": "17",
      "year": "2017"
    },
    {
      "DOI": "10.1214/18-STS644",
      "author": "JS Murray",
      "doi-asserted-by": "publisher",
      "first-page": "142",
      "issue": "2",
      "journal-title": "Stat Sci",
      "key": "495_CR35",
      "unstructured": "Murray JS. Multiple Imputation: a review of practical and theoretical findings. Stat Sci. 2018;33(2):142–59.",
      "volume": "33",
      "year": "2018"
    },
    {
      "DOI": "10.1093/biomet/87.2.329",
      "author": "H Bang",
      "doi-asserted-by": "publisher",
      "first-page": "329",
      "issue": "2",
      "journal-title": "Biometrika",
      "key": "495_CR36",
      "unstructured": "Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000;87(2):329–43.",
      "volume": "87",
      "year": "2000"
    },
    {
      "DOI": "10.1080/15598608.2013.771556",
      "author": "S Chen",
      "doi-asserted-by": "publisher",
      "first-page": "304",
      "issue": "2",
      "journal-title": "J Stat Theory Pract",
      "key": "495_CR37",
      "unstructured": "Chen S, Zhao H. Generalized redistribute-to-the-right algorithm: application to the analysis of censored cost data. J Stat Theory Pract. 2013;7(2):304–23.",
      "volume": "7",
      "year": "2013"
    },
    {
      "DOI": "10.1111/j.0006-341X.2001.01002.x",
      "author": "H Zhao",
      "doi-asserted-by": "publisher",
      "first-page": "1002",
      "issue": "4",
      "journal-title": "Biometrics",
      "key": "495_CR38",
      "unstructured": "Zhao H, Tian L. On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics. 2001;57(4):1002–8.",
      "volume": "57",
      "year": "2001"
    },
    {
      "DOI": "10.1093/biostatistics/1.1.35",
      "author": "DY Lin",
      "doi-asserted-by": "publisher",
      "first-page": "35",
      "issue": "1",
      "journal-title": "Biostatistics",
      "key": "495_CR39",
      "unstructured": "Lin DY. Linear regression analysis of censored medical costs. Biostatistics. 2000;1(1):35–47.",
      "volume": "1",
      "year": "2000"
    },
    {
      "DOI": "10.1002/sim.1377",
      "author": "DY Lin",
      "doi-asserted-by": "publisher",
      "first-page": "1181",
      "journal-title": "Stat Med",
      "key": "495_CR40",
      "unstructured": "Lin DY. Regression analysis of incomplete medical cost data. Stat Med. 2003;22:1181–200.",
      "volume": "22",
      "year": "2003"
    },
    {
      "DOI": "10.1097/00005650-199508000-00009",
      "author": "P Fenn",
      "doi-asserted-by": "publisher",
      "first-page": "851",
      "journal-title": "Med Care",
      "key": "495_CR41",
      "unstructured": "Fenn P, McGuire A, Phillips V, et al. The analysis of censored treatment cost data in economic evaluation. Med Care. 1995;33:851–63.",
      "volume": "33",
      "year": "1995"
    },
    {
      "DOI": "10.1093/biostatistics/1.3.299",
      "author": "GW Carides",
      "doi-asserted-by": "publisher",
      "first-page": "299",
      "journal-title": "Biostatistics",
      "key": "495_CR42",
      "unstructured": "Carides GW, Heyse JF, Iglewicz B. A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics. 2000;1:299–313.",
      "volume": "1",
      "year": "2000"
    },
    {
      "key": "495_CR43",
      "unstructured": "Raikou M, McGuire A. Parametric estimation of medical care costs under conditions of censoring. The London School of Economics and Political Science, 2009;Working paper No. 13/2009, London WC2A 2AE, England."
    },
    {
      "DOI": "10.1002/sim.4295",
      "author": "H Zhao",
      "doi-asserted-by": "publisher",
      "first-page": "2381",
      "issue": "19",
      "journal-title": "Stat Med",
      "key": "495_CR44",
      "unstructured": "Zhao H, Cheng Y, Bang H. Some insight on censored cost estimators. Stat Med. 2011;30(19):2381–8. https://doi.org/10.1002/sim.4295.",
      "volume": "30",
      "year": "2011"
    },
    {
      "DOI": "10.1007/BF03261867",
      "author": "G Kourlaba",
      "doi-asserted-by": "publisher",
      "first-page": "331",
      "issue": "5",
      "journal-title": "Appl Health Econ Health Policy",
      "key": "495_CR45",
      "unstructured": "Kourlaba G, Fragoulakis V, Maniadakis N. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece. Appl Health Econ Health Policy. 2012;10(5):331–42. https://doi.org/10.1007/BF03261867.",
      "volume": "10",
      "year": "2012"
    },
    {
      "DOI": "10.1002/0470856289",
      "author": "AR Willan",
      "doi-asserted-by": "publisher",
      "first-page": "23",
      "key": "495_CR46",
      "unstructured": "Willan AR, Briggs AH. Statistical analysis of cost-effectiveness data. Chichester: John Wiley \u0026 Sons; 2006. p. 23–7.",
      "volume-title": "Statistical analysis of cost-effectiveness data",
      "year": "2006"
    },
    {
      "DOI": "10.1093/eurheartj/ehs149",
      "doi-asserted-by": "publisher",
      "key": "495_CR47",
      "unstructured": "Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M; PLATO Health Economic Substudy Group. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J. 2013;34(3):220–8. https://doi.org/10.1093/eurheartj/ehs149."
    },
    {
      "DOI": "10.1161/CIRCULATIONAHA.120.050850",
      "doi-asserted-by": "publisher",
      "key": "495_CR48",
      "unstructured": "Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, Kamath D, Alhabib K, Bayes-Genis A, Budaj A, Dans ALL, Dzudie A, Probstfield JL, Fox KAA, Karaye KM, Makubi A, Fukakusa B, Teo K, Temizhan A, Wittlinger T, Maggioni AP, Lanas F, Lopez-Jaramillo P, Silva-Cardoso J, Sliwa K, Dokainish H, Grinvalds A, McCready T, Yusuf S; G-CHF Investigators. Health-Related quality of life and mortality in heart failure: the global congestive heart failure study of 23 000 patients from 40 countries. Circulation. 2021;143(22):2129–2142. https://doi.org/10.1161/CIRCULATIONAHA.120.050850."
    },
    {
      "DOI": "10.1007/s40273-020-00984-6",
      "author": "GL Di Tanna",
      "doi-asserted-by": "publisher",
      "first-page": "211",
      "issue": "2",
      "journal-title": "Pharmacoeconomics",
      "key": "495_CR49",
      "unstructured": "Di Tanna GL, Urbich M, Wirtz HS, Potrata B, Heisen M, Bennison C, Brazier J, Globe G. Health state utilities of patients with heart failure: a systematic literature review. Pharmacoeconomics. 2021;39(2):211–29. https://doi.org/10.1007/s40273-020-00984-6.",
      "volume": "39",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.gie.2008.01.035",
      "author": "L Gerson",
      "doi-asserted-by": "publisher",
      "first-page": "920",
      "issue": "5",
      "journal-title": "Gastrointest Endosc",
      "key": "495_CR50",
      "unstructured": "Gerson L, Kamal A. Cost-effectiveness analysis of management strategies for obscure GI bleeding. Gastrointest Endosc. 2008;68(5):920–36. https://doi.org/10.1016/j.gie.2008.01.035.",
      "volume": "68",
      "year": "2008"
    },
    {
      "DOI": "10.1016/j.ajhg.2019.04.017",
      "author": "V Fragoulakis",
      "doi-asserted-by": "publisher",
      "first-page": "1158",
      "issue": "6",
      "journal-title": "Am J Hum Genet",
      "key": "495_CR51",
      "unstructured": "Fragoulakis V, Roncato R, Fratte CD, Ecca F, Bartsakoulia M, Innocenti F, Toffoli G, Cecchin E, Patrinos GP, Mitropoulou C. Estimating the effectiveness of DPYD genotyping in Italian individuals suffering from cancer based on the cost of chemotherapy-induced toxicity. Am J Hum Genet. 2019;104(6):1158–68. https://doi.org/10.1016/j.ajhg.2019.04.017.",
      "volume": "104",
      "year": "2019"
    },
    {
      "DOI": "10.1186/s12955-020-01407-y",
      "author": "MB Betts",
      "doi-asserted-by": "publisher",
      "first-page": "251",
      "issue": "1",
      "journal-title": "Health Qual Life Outcomes",
      "key": "495_CR52",
      "unstructured": "Betts MB, Rane P, Bergrath E, Chitnis M, Bhutani MK, Gulea C, Qian Y, Villa G. Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review. Health Qual Life Outcomes. 2020;18(1):251. https://doi.org/10.1186/s12955-020-01407-y.",
      "volume": "18",
      "year": "2020"
    },
    {
      "DOI": "10.1023/a:1012597123667",
      "author": "DK Blough",
      "doi-asserted-by": "publisher",
      "first-page": "185",
      "issue": "2",
      "journal-title": "Methodology",
      "key": "495_CR53",
      "unstructured": "Blough DK, Ramsey SD. Health services and outcomes research. Methodology. 2000;1(2):185–202. https://doi.org/10.1023/a:1012597123667.",
      "volume": "1",
      "year": "2000"
    },
    {
      "DOI": "10.1177/0272989X0202200408",
      "author": "AH Briggs",
      "doi-asserted-by": "publisher",
      "first-page": "290",
      "issue": "4",
      "journal-title": "Med Decis Making",
      "key": "495_CR54",
      "unstructured": "Briggs AH, Goeree R, Blackhouse G, O’Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22(4):290–308. https://doi.org/10.1177/0272989X0202200408.",
      "volume": "22",
      "year": "2002"
    },
    {
      "key": "495_CR55",
      "unstructured": "https://www.sspa.juntadeandalucia.es/servicioandaluzdesalud/profesionales/relacion-con-la-ciudadania/precios-publicos"
    },
    {
      "DOI": "10.1002/1097-0258(20001215)19:23\u003c3219::AID-SIM623\u003e3.0.CO;2-P",
      "author": "JA Barber",
      "doi-asserted-by": "publisher",
      "first-page": "3219",
      "issue": "23",
      "journal-title": "Stat Med",
      "key": "495_CR56",
      "unstructured": "Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19(23):3219–36.",
      "volume": "19",
      "year": "2000"
    },
    {
      "author": "TJ Diciccio",
      "first-page": "338",
      "journal-title": "J R Stat Soc Ser B Stat Methodol",
      "key": "495_CR57",
      "unstructured": "Diciccio TJ, Romano JP. A review of bootstrap confidence intervals. J R Stat Soc Ser B Stat Methodol. 1988;50:338–54.",
      "volume": "50",
      "year": "1988"
    },
    {
      "DOI": "10.1146/annurev.publhealth.23.100901.140534",
      "author": "AH Briggs",
      "doi-asserted-by": "publisher",
      "first-page": "377",
      "journal-title": "Ann Rev Public Health",
      "key": "495_CR58",
      "unstructured": "Briggs AH, O’Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Ann Rev Public Health. 2002;23:377–401. https://doi.org/10.1146/annurev.publhealth.23.100901.140534.",
      "volume": "23",
      "year": "2002"
    },
    {
      "DOI": "10.1177/0272989X15586552",
      "author": "J Thorn",
      "doi-asserted-by": "publisher",
      "first-page": "285",
      "issue": "3",
      "journal-title": "Med Decis Mak",
      "key": "495_CR59",
      "unstructured": "Thorn J, Coast J, Andronis L. Interpretation of the expected value of perfect information and research recommendations: a systematic review and empirical investigation. Med Decis Mak. 2016;36(3):285–95. https://doi.org/10.1177/0272989X15586552.",
      "volume": "36",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.jval.2020.01.001",
      "author": "E Fenwick",
      "doi-asserted-by": "publisher",
      "first-page": "139",
      "issue": "2",
      "journal-title": "Value Health",
      "key": "495_CR60",
      "unstructured": "Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, Koffijberg HE, Strong M, Sanders Schmidler GD, Rothery C. Value of information analysis for research decisions-an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force. Value Health. 2020;23(2):139–50. https://doi.org/10.1016/j.jval.2020.01.001.",
      "volume": "23",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41397-019-0069-1",
      "author": "V Fragoulakis",
      "doi-asserted-by": "publisher",
      "first-page": "438",
      "issue": "5",
      "journal-title": "Pharmacogenomics J",
      "key": "495_CR61",
      "unstructured": "Fragoulakis V, Bartsakoulia M, Díaz-Villamarín X, Chalikiopoulou K, Kehagia K, Ramos JGS, Martínez-González LJ, Gkotsi M, Katrali E, Skoufas E, Vozikis A, John A, Ali BR, Wordsworth S, Dávila-Fajardo CL, Katsila T, Patrinos GP, Mitropoulou C. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention. Pharmacogenomics J. 2019;19(5):438–45. https://doi.org/10.1038/s41397-019-0069-1.",
      "volume": "19",
      "year": "2019"
    },
    {
      "DOI": "10.1007/s40256-021-00496-4",
      "author": "DMF Claassens",
      "doi-asserted-by": "publisher",
      "first-page": "195",
      "issue": "2",
      "journal-title": "Am J Cardiovasc Drugs",
      "key": "495_CR62",
      "unstructured": "Claassens DMF, van Dorst PWM, Vos GJA, Bergmeijer TO, Hermanides RS, van’t Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Postma MJ, Deneer VHM, Ten Berg JM, Boersma C. Cost effectiveness of a CYP2C19 genotype-guided strategy in patients with acute myocardial infarction: results from the popular genetics trial. Am J Cardiovasc Drugs. 2022;22(2):195–206. https://doi.org/10.1007/s40256-021-00496-4.",
      "volume": "22",
      "year": "2022"
    },
    {
      "DOI": "10.1093/ehjqcco/qcac031",
      "author": "OM Dong",
      "doi-asserted-by": "publisher",
      "first-page": "qcac031",
      "journal-title": "Eur Heart J Qual Care Clin Outcomes.",
      "key": "495_CR63",
      "unstructured": "Dong OM, Friede KA, Chanfreau-Coffinier C, Voora D. Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. Eur Heart J Qual Care Clin Outcomes. 2022;2:qcac031. https://doi.org/10.1093/ehjqcco/qcac031.",
      "volume": "2",
      "year": "2022"
    },
    {
      "DOI": "10.1038/s41598-021-86824-9",
      "author": "Z Cai",
      "doi-asserted-by": "publisher",
      "first-page": "7383",
      "issue": "1",
      "journal-title": "Sci Rep",
      "key": "495_CR64",
      "unstructured": "Cai Z, Cai D, Wang R, Wang H, Yu Z, Gao F, Liu Y, Kang Y, Wu Z. Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack. Sci Rep. 2021;11(1):7383. https://doi.org/10.1038/s41598-021-86824-9.",
      "volume": "11",
      "year": "2021"
    },
    {
      "DOI": "10.1002/j.1875-9114.2012.01048.Erratum.In:Pharmacotherapy.2012Jun;32(6):581",
      "author": "ES Reese",
      "doi-asserted-by": "publisher",
      "first-page": "323",
      "issue": "4",
      "journal-title": "Pharmacotherapy",
      "key": "495_CR65",
      "unstructured": "Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy. 2012;32(4):323–32. https://doi.org/10.1002/j.1875-9114.2012.01048.Erratum.In:Pharmacotherapy.2012Jun;32(6):581.",
      "volume": "32",
      "year": "2012"
    },
    {
      "DOI": "10.2217/pgs-2017-0075",
      "author": "MS Borse",
      "doi-asserted-by": "publisher",
      "first-page": "1155",
      "issue": "12",
      "journal-title": "Pharmacogenomics",
      "key": "495_CR66",
      "unstructured": "Borse MS, Dong OM, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. Pharmacogenomics. 2017;18(12):1155–66. https://doi.org/10.2217/pgs-2017-0075.",
      "volume": "18",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s41397-020-0162-5",
      "author": "NA Limdi",
      "doi-asserted-by": "publisher",
      "first-page": "724",
      "issue": "5",
      "journal-title": "Pharmacogenomics J",
      "key": "495_CR67",
      "unstructured": "Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, Diaby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF. Implementing GeNomics In pracTicE (IGNITE) Network Pharmacogenetic Working Group (IGNITE-PGx). Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics J. 2020;20(5):724–35. https://doi.org/10.1038/s41397-020-0162-5.",
      "volume": "20",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41397-020-00204-6",
      "author": "JH Kim",
      "doi-asserted-by": "publisher",
      "first-page": "243",
      "issue": "2",
      "journal-title": "Pharmacogenomics J",
      "key": "495_CR68",
      "unstructured": "Kim JH, Tan DS, Chan M. Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore. Pharmacogenomics J. 2021;21(2):243–50. https://doi.org/10.1038/s41397-020-00204-6.",
      "volume": "21",
      "year": "2021"
    },
    {
      "DOI": "10.1111/jth.12059",
      "author": "A Lala",
      "doi-asserted-by": "publisher",
      "first-page": "81",
      "issue": "1",
      "journal-title": "J Thromb Haemost",
      "key": "495_CR69",
      "unstructured": "Lala A, Berger JS, Sharma G, Hochman JS, Scott Braithwaite R, Ladapo JA. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. J Thromb Haemost. 2013;11(1):81–91. https://doi.org/10.1111/jth.12059.",
      "volume": "11",
      "year": "2013"
    },
    {
      "DOI": "10.1038/tpj.2017.21",
      "author": "M Verbelen",
      "doi-asserted-by": "publisher",
      "first-page": "395",
      "issue": "5",
      "journal-title": "Pharmacogenomics J",
      "key": "495_CR70",
      "unstructured": "Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17(5):395–402. https://doi.org/10.1038/tpj.2017.21.",
      "volume": "17",
      "year": "2017"
    },
    {
      "DOI": "10.1038/clpt.2011.303",
      "author": "GF Guzauskas",
      "doi-asserted-by": "publisher",
      "first-page": "829",
      "issue": "5",
      "journal-title": "Clin Pharmacol Ther",
      "key": "495_CR71",
      "unstructured": "Guzauskas GF, Hughes DA, Bradley SM, Veenstra DL. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. Clin Pharmacol Ther. 2012;91(5):829–37. https://doi.org/10.1038/clpt.2011.303.",
      "volume": "91",
      "year": "2012"
    }
  ],
  "reference-count": 71,
  "references-count": 71,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-023-00495-3"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "17"
}